AdvanSix(ASIX) - 2025 Q3 - Earnings Call Presentation

Financial Performance - 3Q25 sales were $374 million, a decrease of 6% year-over-year[6,10] - Adjusted EBITDA for 3Q25 was $25 million, a decrease of $28 million year-over-year[6,10] - Adjusted EBITDA margin for 3Q25 was 6.6%, a decrease of 680 basis points year-over-year[10] - The company reported a net loss of $3 million and EPS of -$0.10 for 3Q25[7] - Adjusted EPS for 3Q25 was $0.08[8] Product Line Performance - Plant Nutrients sales were $139 million, an increase of 22% year-over-year[15] - Chemical Intermediates sales were $84 million, a decrease of 27% year-over-year[15] - Nylon sales were $79 million, a decrease of 16% year-over-year[15] - Caprolactam sales were $73 million, a decrease of 4% year-over-year[15] Cash Flow and Capital Expenditure - 2025 Capex is now expected to be $120 million-$125 million, reflecting $30 million full year cash conservation[8] - Expect Capex of $125 million-$135 million in 2026[23] - The company is targeting positive free cash flow for 2025[21]